CardioDynamics Announces Results of Three Significant BioZ Thoracic Electrical Bioimpedance Studies.

SAN DIEGO--(BW HealthWire)--Sept. 28, 1999--

CardioDynamics International Corporation (Nasdaq:CDIC), manufacturer of BioZb noninvasive digital cardiac output monitoring systems, announced the results of three significant BioZ clinical studies which were presented at the Third Annual Heart Failure Society (HFSA) Scientific Meeting in San Francisco.

The studies demonstrated that CardioDynamics' proprietary Thoracic Electrical Bioimpedance (TEB) technology accurately and inexpensively measures cardiac performance in both hospital critical care units and outpatient physician office settings. The studies also validated the BioZ's importance as a useful and reliable tool in treating advanced heart failure patients being supported and weaned from surgical therapies, such as implantable left ventricular assist devices (LVADs).

Commenting on his LVAD study, Marc A. Silver, M.D., Director of the Heart Failure Institute at Christ Hospital and Medical Center, Oak Lawn, Illinois, stated, "The BioZ's noninvasive measurement of cardiac output (CO) in patients with LVADs is accurate and useful in assessing the ability to wean patients and determining the degree of recovery of left ventricular function during periods of reduced LVAD support. I believe the BioZ's cost-effective technology will become a clinically acceptable method in assessing and treating heart failure patients."

Dr. Silver's second study, The BioZ Utility and Economic Benefit in Critical Care Patients, demonstrated the utility and economic benefit of using the BioZ's TEB technology in the critical care unit. The study verified that hemodynamic measurements, utilizing the BioZ, are rapid, with lower risk, and may markedly reduce costs when compared to Pulmonary Artery Catheterization (PAC) procedures. Dr. Silver commenting on the study results, stated, "By utilizing the BioZ, safer and more cost-effective care can be delivered in a critical care setting, as compared to PACs."

Although the PAC procedure currently is the method most commonly used for hemodynamic assessment, the associated complications are as high as 25% and include arrhythmias, infection, pulmonary artery rupture, and death. These potential complications require patients to be carefully monitored in expensive critical care hospital departments. In contrast, the BioZ's no-risk, low-cost technology broadens hemodynamic availability to additional hospital departments and physician offices. These newly accessible markets account for $2 billion of the total $4 billion BioZ market.

Barry H. Greenberg, M.D., Director of the Heart Failure and Cardiac Transplantation Program at the University of California, San Diego, also presented the results of his BioZ Reproducibility Study. This study reported that the BioZ is highly reproducible, can be rapidly and inexpensively obtained in an outpatient setting, and can accurately detect the effects medications and the deterioration of cardiac function over time.

Michael K. Perry, Chief Executive Officer of CardioDynamics, stated, "These three significant studies augment the results of seven recently presented clinical studies and validate the BioZ's ability to improve heart failure patient treatment. These studies highlight the BioZ's contribution toward reducing the $52 billion annual costs associated with this fatal disease and move us closer to establishing the BioZ as the Sixth Vital Sign(TM)."

Company Description

CardioDynamics, with headquarters in San Diego, is committed to fundamentally changing the way hemodynamic monitoring is performed in healthcare. The Company's primary products, the BioZb System, BioZ Portable, and BioZ.com, utilize its Thoracic Electrical Bioimpedance (TEB) technology to noninvasively obtain data on a wide range of hemodynamic parameters. There are 275 BioZb systems now in use in major medical centers including the May Clinic (Rochester), UCSF Stanford Health Care (Palo Alto), Yale New Haven Hospital (New Haven), and Baylor College of Medicine (Houston). The worldwide market potential for BioZ products is estimated to be $4 billion, together with an additional $800 million in recurring annual revenue for disposables. For additional information, please refer to the Company's web site at www.cardiodynamics.com.

Forward-Looking (Safe Harbor) Statement:

Note: Except for the historical and factual information contained herein, this press release contains forward-looking statements, the accuracy of which are necessarily subject to uncertainties and risks, which include sole dependence on the BioZ product line, competition from Baxter Healthcare Corp. (manufacturer of the Swan-Ganz device), further capital requirements, and various uncertainties characteristic of companies just emerging from the development stage; as well as other risks detailed in the Company's filings with the SEC, including its 1998 Form 10-KSB. The Company does not undertake to update the disclosures contained in this press release.